Trial Profile
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Navitoclax (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.